• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trust Your Gut--USANA's Probiotic Earns ConsumerLab.com Seal of Approval

    12/16/25 7:20:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- USANA (NYSE:USNA), the global leader in cellular nutrition, is proud to announce that its top-rated Probiotic supplement has earned the distinguished ConsumerLab.com Seal of Approval. This respected third-party certification recognizes products that meet the highest standards for purity, potency, and scientific accuracy.  

    USANA's Probiotic Earns ConsumerLab.com Seal of Approval

    Gut health continues to rise as one of today's most talked-about wellness priorities, with growing scientific evidence linking the microbiome to digestion, immunity, and overall well-being. USANA's Probiotic delivers a precisely balanced blend of beneficial bacteria formulated to support healthy digestion, nutrient absorption, and everyday wellness.*

    "This certification is a powerful validation of the standards we hold ourselves to," said Brent Neidig, USANA Chief Commercial Officer. "We are dedicated to providing our Brand Partners and customers with premium, high-quality products they can trust. We're proud to offer a probiotic supplement that empowers individuals to take control of their gut health with confidence."

    To earn the Seal of Approval, USANA's Probiotic supplement underwent comprehensive, independent testing for potency, purity, viability, and label accuracy. It was required to deliver its stated levels of live, active bacterial strains through expiration, and pass all contaminant testing—benchmarks that align with USANA's own uncompromising quality standards.

    Small Pack, Big Impact: Inside USANA's Gut-Nourishing Probiotic

    USANA's Probiotic provides a powerful, scientifically supported blend of beneficial bacteria in a convenient, travel-friendly stick pack—designed to fit into any lifestyle. Because when it comes to overall wellness, nurturing your gut microbiome is foundational for optimal health.

    Inside USANA's Probiotic, you'll find:

    • Lactobacillus rhamnosus GG (LGG®) – One of the world's most researched probiotic strains, known for supporting healthy digestion, natural immune defenses, and a balanced microbiome.*
    • Bifidobacterium BB-12® – A clinically studied strain that helps maintain digestive comfort, supports beneficial gut flora, and aids nutrient metabolism.*
    • Survivability and Stability Technology – USANA's advanced formulation helps ensure bacteria remain viable through manufacturing, storage, and digestion for reliable, effective support.*

    ConsumerLab.com's approval reinforces USANA's reputation as a leader in scientific innovation and product quality. Through continuous investment in research, state-of-the-art manufacturing, and gold-standard testing protocols, USANA remains committed to delivering premium nutritional products that not only meet but exceed industry expectations.

    Experience the power of premium microbiome support. Visit USANA.com to learn how USANA's award-winning products bring science and wellness together.



    *These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    About USANA

    USANA (NYSE:USNA) has been providing premium-quality nutrition and lifestyle products for more than 30 years. From its award-winning supplements manufactured in its FDA-registered facility to its cutting-edge Celavive skincare and healthy living products, USANA is committed to empowering people to live healthier, more vibrant lives.

    Discover the future of nutrition at USANA.com or explore the science at AskTheScientists.com.

    Media Contact:

    (801) 954-7645

    media(at)USANAinc(dot)com

    USANA Logo (PRNewsfoto/USANA)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trust-your-gutusanas-probiotic-earns-consumerlabcom-seal-of-approval-302642809.html

    SOURCE USANA

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Executive Chairman Kevin Guest Shares Timeless Lessons for a 2026 Growth Mindset

    SALT LAKE CITY, Jan. 5, 2026 /PRNewswire/ -- As leaders everywhere set sights on the new year, Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA), is encouraging professionals to embrace a growth mindset as the key to lasting achievement and fulfillment. "Success is about the experiences you have, the relationships you build, and the lessons you apply," said Guest, who is also the author of the bestseller, All the Right Reasons: 12 Principles for Living a Life in Harmony. For the international leader, whose company operates in 25 countries, four traits stand

    1/5/26 7:13:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INFORMATION OFFICER Benedict Peter sold $56,001 worth of shares (2,673 units at $20.95), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    12/11/25 11:21:37 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF SALES OFFICER Mulham David Mulham sold $18,333 worth of shares (873 units at $21.00), decreasing direct ownership by 9% to 8,387 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    12/11/25 11:25:25 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Winssinger Frederic J sold $38,420 worth of shares (2,000 units at $19.21), decreasing direct ownership by 25% to 5,986 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    11/10/25 5:20:51 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/12/26 6:29:11 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/8/26 9:01:18 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    11/5/25 5:11:01 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

    10/20/25 5:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care